Corona Remedies launched its ₹655 crore IPO on December 8 with a price band of ₹1,008–1,062 per share.
On the first day, the issue saw 33% subscription, with 14.75 lakh shares bid against 45.71 lakh shares on offer. The grey-market is trading at a premium of around ₹290, indicating positive investor sentiment.
The company reported FY25 revenue of ₹1,196 crore, EBITDA of ₹246 crore, and a profit after tax of ₹149.43 crore, reflecting strong financials.
The subscription window closes December 10, with listing expected on BSE/NSE around December 15, making it a closely watched IPO.